Dainippon Sumitomo Obtains Caner Drug Rights From Boston Biomedical
This article was originally published in PharmAsia News
Dainippon Sumitomo Pharma will pay an upfront $15 million to Boston Biomedical for exclusive rights in Japan to develop and market BB1608, an anticancer agent targeting stem cells
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.